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ABSTRACT The actin cytoskeleton and its network of associated proteins constitute a physical barrier that viruses must circum-
vent to gain entry into cells for productive infection. The mechanisms by which the physical signals of infection are sensed by the
host to activate an innate immune response are not well understood. The antiviral endoribonuclease RNase L is ubiquitously
expressed in a latent form and activated upon binding 2-5A, a unique oligoadenylate produced during viral infections. We pro-
vide evidence that RNase L in its inactive form interacts with the actin-binding protein Filamin A to modulate the actin cytoskel-
eton and inhibit virus entry. Cells lacking either RNase L or Filamin A displayed increased virus entry which was exacerbated in
cells lacking both proteins. RNase L deletion mutants that reduced Filamin A interaction displayed a compromised ability to
restrict virus entry, supporting the idea of an important role for the RNase L-Filamin A complex in barrier function. Remark-
ably, both the wild type and a catalytically inactive RNase L mutant were competent to reduce virus entry when transfected into
RNase L-deficient cells, indicating that this novel function of RNase L is independent of its enzymatic activity. Virus infection
and RNase L activation disrupt its association with Filamin A and release RNase L to mediate its canonical nuclease-dependent
antiviral activities. The dual functions of RNase L as a constitutive component of the actin cytoskeleton and as an inducedmedi-
ator of antiviral signaling and effector functions provide insights into its mechanisms of antiviral activity and opportunities for
the development of novel antiviral agents.
IMPORTANCE Cells constantly face and sample pathogens on their outer surface. The actin cytoskeleton and interacting proteins
associate with the cell membrane and constitute a barrier to infection. Disruption of the actin cytoskeleton allows viruses to en-
ter the cell and induces innate immune responses to clear infections. The molecular mechanisms that link virus-induced physical
perturbations to host defense pathways remain unclear. Our studies identified a novel interaction between the antiviral endori-
bonuclease RNase L and the actin-binding protein Filamin A that enhances host defense by preventing viral entry into naive
cells. This role for RNase L is independent of its enzymatic function. Virus infection alters actin dynamics, disrupts the RNase
L-Filamin A complex, and releases RNase L to mediate antiviral signaling and effector functions via its established nucleolytic
activities. These dual roles for RNase L provide an efficient strategy to protect cells from infection and rapidly respond upon
pathogen exposure.
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Viral infection is initiated by attachment to its cellular recep-tors. The subsequent activation of receptor-mediated endo-
cytosis results in actin clustering and perturbation of the actin
cytoskeleton (1). The disruption of barrier function provided by
the actin cytoskeleton is a central component of infection by di-
verse pathogens and exposes viral pathogen-associated molecular
patterns (PAMPs) to host pattern recognition receptors (PRRs)
that activate an innate immune response (2–4). Pathogen recog-
nition by PRRs results in the induction of cytokines and chemo-
kines, including type I interferon (IFN), that mediate pleiotropic
activities to clear viral infections (4). Consistent with a key role for
disruption of the actin cytoskeleton in virus infection, viruses have
evolved strategies to perturb this barrier by targeting actin-
binding proteins. For instance, the actin-binding protein Rac1
GTPase is required for actin remodeling to facilitate entry, virus
production, and release of dengue virus and coxsackievirus (5, 6).
Influenza virus interacts with the actin cytoskeleton in all stages of
the viral life cycle, including entry, replication, antiviral signaling,
and intracellular trafficking, for egress in polarized cells (7).
Gelsolin, an actin-severing protein, restricts human immunodefi-
ciency virus type 1 (HIV-1) infection in a prefusion step and is
inhibited by the IFN-regulated antiviral RNA-dependent protein
kinase PKR (8, 9). Recent studies have implicated AMP-related
protein kinase (AMPK) activity in actin polymerization that in-
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creased entry of both vaccinia virus and Ebola virus (10, 11). Thus,
while pathogen targeting of actin-binding proteins as a strategy to
promote infection is well established, less is known about how the
physical disruption of the actin cytoskeleton is sensed by the host
to activate established innate immune effectors.
Filamin A is a multifunctional actin-binding protein which
cross-links actin filaments into a network through its N-terminal
actin-binding domain (ABD). The C-terminal -sheets form
immunoglobulin-like domains that provide interfaces for
protein-protein interactions. In this manner, Filamin A serves as a
scaffold to connect the actin cytoskeleton with over 60 function-
ally diverse cellular proteins, including membrane receptors, sig-
naling molecules, and DNA repair proteins. In the context of
pathogen-host interactions, Filamin A serves as an adaptor pro-
tein that links HIV-1 receptors to the actin cytoskeleton to pro-
mote viral entry (12, 13) and associates with viral NS3 and NS5A
proteins in chronic hepatitis C virus (HCV) infection (14). Fil-
amin A binds to Integrin 1 (15), and integrins are receptors for
adenoviruses and coxsackievirus. These viruses use Filamin A as
an adaptor to connect receptor binding to the actin cytoskeleton
that is required for their life cycles (16, 17). Filamin A thus func-
tions in infection by diverse viral pathogens; however, little is
known about its interactions with components of the host innate
immune response.
RNase L is a unique endoribonuclease that is activated during
viral infections or in cells treated with IFN (18–20). IFN induces
transcription of IFN-stimulated genes (ISGs), including 2=-5=-
oligoadenylate synthetase (OAS). OAS proteins are activated by
viral double-stranded RNA (dsRNA) PAMPs to produce 2-5A
[px5=A(2=p5=A)n, where x 1 to 3 andn2] from cellular ATP,
which in turn binds specifically to the latent endoribonuclease,
RNase L (21). To date, the only well-established function of 2-5A
is activation of RNase L. 2-5A binding promotes dimerization of
RNase L and converts it to an active enzyme (21, 22). Activated
RNase L cleaves single-stranded viral and host RNAs to mediate its
antiviral and antiproliferative activities (23, 24). Thus, in the con-
text of virus infection, RNase L is thought to function after release
of viral nucleic acids and interferon production to activate OAS
and synthesize 2-5A from ATP. Structure-function analysis of
RNase L revealed that the R667A substitution inhibits endoribo-
nuclease activity (nuclease dead) and that the R462Q substitution
impairs the ability of RNase L to dimerize (25–28). In addition to
the direct cleavage of viral RNA to inhibit replication, the products
of RNase L cleavage include small RNA with duplex structures
which can signal through the RIG-I-like helicases RIG-I (retinoic
acid-inducible gene I) and MDA5 (melanoma differentiation-
associated protein 5) to amplify the production of IFN- (29).
In addition to the established roles of RNase L as an antiviral
protein that require its endoribonuclease activity, RNase L inter-
acts with several cellular proteins that may provide alternative
mechanisms by which it mediates biological functions. For exam-
ple, RNase L interacts with IQGAP1 (an IQ [isoleucine-
glutamine] motif containing GTPase activating protein 1) (30),
which functions as an assembly scaffold for the organization of a
multimolecular complex and could interface with incoming sig-
nals to induce reorganization of the actin cytoskeleton. The inter-
action with IQGAP1 may thus position RNase L to respond to
viral pathogens that target the actin cytoskeleton. Recent studies
have identified interactions of RNase L with extracellular matrix
(ECM) and cytoskeletal proteins (31). In this regard, RNase L has
been shown to regulate tight-junction proteins and maintain bar-
rier integrity in intestinal epithelial cells during enteropathogenic
Escherichia coli infection (32). Relatedly, RNase L interacts with
the androgen receptor (AR) (33) that, in turn, interacts with Fil-
amin A (34). These observations suggested that RNase L may
modulate the cytoskeleton. Therefore, we investigated a potential
interaction of RNase L with Filamin A that may influence the
cellular actin network. Here we identify Filamin A as a novel
RNase L interacting protein under resting, uninfected conditions.
This interaction functioned to limit viral entry via a mechanism
that is independent of RNase L enzymatic activity and virus-
induced production of 2-5A. Consistent with this role, activation
of RNase L by 2-5A or viral infections disrupted the interaction,
leading to canonical RNase L activity in antiviral signaling. Cells
lacking either RNase L or Filamin A or lacking both proteins ex-
hibited an altered actin cytoskeleton, enhanced entry of virus, and
compromised antiviral activity, supporting the idea of an impor-
tant function for this interaction. Together, these studies identi-
fied a previously unrecognized nonenzymatic role for RNase L to
inhibit virus entry through interaction with Filamin A.
RESULTS
RNase L interacts with Filamin A and dissociates upon activa-
tion. RNase L was reported to interact with the androgen receptor
(AR) which also interacts with Filamin A, suggesting that RNase L
may interact, directly or indirectly, with Filamin A. To determine
if these proteins associate in cells, HEK293T cells were transfected
with Flag-RNase L and Myc-Filamin A. Immunoprecipitation
(IP) of either RNase L or Filamin A from transfected cells demon-
strated the presence of Filamin A or RNase L in IP complexes,
respectively (Fig. 1A). An N-terminal proteolytic product of Fil-
amin A is also detected as has been reported in other cells (34, 35).
HEK293T cells do not express androgen receptor, suggesting that
the interaction is independent of the presence of the AR. We fur-
ther confirmed the interaction of RNase L and Filamin A in
HT1080 cells (data not shown). RNase L has a modular structure
with an N-terminal ankyrin repeat region that contains the sites
for binding of its activator, 2-5A, a C-terminal nuclease domain,
and a kinase-like domain in the middle of the protein (Fig. 1B). To
identify the region of RNase L that interacts with Filamin A, we
used RNase L deletion constructs that comprised N-terminal res-
idues 1 to 335 (C, lacking nuclease domain) or C-terminal resi-
dues 386 to 741 (N, lacking ankyrin repeats) in coimmunopre-
cipitation experiments with full-length Myc-Filamin A.
Interaction of theC RNase L protein with Filamin A was slightly
reduced compared to that seen with full-length RNase L; however,
deletion of the N-terminal residues, including the ankyrin repeats
in the N construct, abrogated Filamin A binding (Fig. 1C; see
also Fig. S2 in the supplemental material). These results suggested
that the N-terminal half of RNase L is essential for Filamin A
interaction and that, while they are not required, the C-terminal
residues may impact the interaction by affecting protein folding.
To determine if endogenous Filamin A can bind to RNase L, we
used HeLa cells which express very small amounts of RNase L
protein (36) that were reconstituted with a vector alone, wild-type
(WT) RNase L, or RNase L point mutants R667A and R462Q,
which render the enzyme nuclease dead and dimerization defi-
cient, respectively (36, 37). Filamin A coimmunoprecipitated with
WT RNase L and to comparable levels with mutant forms of the
protein, suggesting that the interaction did not require the enzy-
Malathi et al.
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matic or dimerization capacities of RNase L (Fig. 1D). RNase L is
expressed as an inactive monomer in the absence of its 2-5A acti-
vator that is produced in response to virus infection or IFN treat-
ment. To analyze the impact of RNase L activation on its interac-
tion with Filamin A in the context of viral infection, cells
expressing Filamin A and WT or nuclease-dead (R667A) RNase L
were infected with encephalomyocarditis virus (EMCV), which is
known to activate RNase L (29, 38, 39), or left uninfected. Inter-
estingly, the interaction between Filamin A and either WT or
nuclease-dead RNase L decreased significantly following virus in-
fection (Fig. 1E). This finding suggested that RNase L activation
during viral infection results in its dissociation from a Filamin A
complex. To directly demonstrate that 2-5A-induced activation of
RNase L results in its dissociation from Filamin A in cells,
HEK293T cells expressing Flag-RNase L and Myc-Filamin A were
transfected with 2-5A. Immunoprecipitation of RNase L indicated
that its interaction with Filamin A was indeed reduced in the pres-
ence of 2-5A compared to the results seen with untreated cells
(Fig. 1F). These results suggested that RNase L interacts with Fil-
amin A under basal, unstimulated conditions but that the inter-
action is disrupted when RNase L is activated during viral infec-
tions.
Actin dynamics are altered in cells lacking RNase L. Actin
networks define cell shape, mediate motility and migration, and
are an important target for invading pathogens (1, 2). Filamin A
modulates actin dynamics, and its interaction with RNase L sug-
FIG 1 RNase L interacts with Filamin A in uninfected cells and dissociates upon activation. (A) HEK293T cells expressing Flag-RNase L and Myc-Filamin A or
Flag and Myc tag vector alone were immunoprecipitated with Flag-M2 agarose beads, Myc-EZview agarose beads, or control IgG. The samples were separated on
SDS-PAGE, and the presence of interacting proteins was determined by immunoblot analysis. WB, Western blot analysis. (B) Domain organization and key
features of RNase L and mutants used in this study. (C) Myc-Filamin A and Flag-RNase L (full length [FL]), Flag-RNase L (C), or Flag-RNase L (N) were
immunoprecipitated using Flag-M2 agarose beads or control IgG. Blots were probed with anti-Myc or anti-Flag antibodies. For the IP analysis whose results are
presented in panels C to F, 5% of the immunoprecipitate was loaded in blots probed with the antibodies indicated. (D) HeLa M cells stably expressing pcDNA3
vector, RNase L WT, RNase L R667A, or RNase L R462Q were immunoprecipitated with anti-Filamin A antibodies or control IgG. Endogenous Filamin A and
coimmunoprecipitated RNase L proteins were detected on immunoblots using specific antibodies. IgG heavy chain is indicated by an arrow. (E) HEK293T cells
expressing Flag-RNase L or Flag-RNase L R667A and Myc-Filamin A were infected with EMCV (MOI  1.0) for 1 h or left uninfected. Cell lysates were
immunoprecipitated with Flag-M2 agarose beads or control IgG. Samples were subjected to immunoblot analysis using anti-Flag or anti-Myc antibodies. (F)
HEK293T cells expressing Flag-RNase L and Myc-Filamin A were transfected with 10 M 2-5A for 1 h followed by immunoprecipitation and immunoblot
analysis performed as described above. Protein expression in all lysates was normalized to -actin levels. Data are representative of the results of 3 independent
experiments.
Antiviral Roles of RNase L-Filamin A Interaction
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gested that RNase L deficiency may impact the actin cytoskeleton.
Consistent with this prediction, WT and RNase L-knockout (KO)
mouse embryonic fibroblasts (MEFs) exhibited distinct morphol-
ogies that may reflect alterations in the actin cytoskeleton. There-
fore, we examined the organization of filamentous actin in RNase
L KO and WT MEFs by staining with Alexa 488-labeled phalloi-
din. The immunofluorescence staining was analyzed using a Leica
TCS SP5 multiphoton laser scanning confocal microscope
(Fig. 2A). Quantification of the mean fluorescence intensity of
stained cells normalized to surface area revealed a significant
(30%) reduction in the total number of actin filaments in RNase L
KO compared to WT MEFs (Fig. 2B). Alterations in the actin
cytoskeleton are associated with functional changes, including
macropinosome formation and nonselective particle uptake, that
also serve as mechanisms for viral entry (40–42). To determine if
the altered actin network observed in RNase L KO MEFs led to the
induction of macropinocytosis, we compared endocytic activity
levels in WT RNase L and KO MEFs by monitoring the uptake of
soluble fluorescein isothiocyanate (FITC)-labeled dextran. RNase
L KO MEFs showed a 5-fold increase in endocytic uptake as evi-
denced by the appearance of FITC-dextran granules in the cyto-
plasm, whereas most of the staining remained on the periphery of
the WT cells (Fig. 2C and D). These results suggested that RNase L
plays a role in regulating actin dynamics and actin-mediated cel-
lular processes and that these functions may be mediated, in part,
by its interaction with Filamin A.
RNase L enzymatic activity is not affected by Filamin A or
disruption of the actin cytoskeleton. Our data indicate that
RNase L associates with Filamin A under basal conditions and
dissociates upon 2-5A-mediated activation (Fig. 1). To determine
if the presence of Filamin A impacts RNase L enzymatic activity,
we utilized the M2 melanoma cell line that lacks Filamin A mRNA
and protein expression (43) and does not express detectable
RNase L (Fig. 3A). To analyze RNase L activity in the presence and
absence of Filamin A, M2 cell lines stably transfected with Filamin
A and with either WT or catalytically inactive RNase L were gen-
erated and protein expression was validated by immunoblot anal-
ysis (Fig. 3A). Each cell line was then transfected with 2-5A to
activate RNase L or mock transfected and analyzed for RNase L
activity. 2-5A-induced activation of RNase L results in the cleav-
age of rRNA into discrete fragments that can be quantified as a
measure of RNase L activity in cells (29, 44, 45). 2-5A transfection
of M2 cells expressing WT but not catalytically inactive RNase L
induced characteristic rRNA cleavage products in a manner inde-
pendent of Filamin A expression (compare lanes 5 and 11 in
Fig. 3B). Thus, consistent with the 2-5A-induced dissociation of
Filamin A and RNase L (Fig. 1F), Filamin A did not alter the
enzymatic activity of RNase L. Since RNase L deficiency resulted in
a reduction in the levels of filamentous actin (Fig. 2A and B) that
might have occurred via its interaction with Filamin A, we next
determined if perturbation of actin filaments impacted RNase L
activity. HT1080 cells that express functional endogenous RNase
FIG 2 RNase L regulates actin dynamics. (A) WT and RNase L KO primary MEFs were stained with Alexa 488 phalloidin to detect actin filaments (F-actin). (B)
Total F-actin amounts were analyzed from 10 fields of MEFs from three independent experiments stained as described above and quantitated using ImageJ
software. (C) Fluid-phase uptake of FITC-dextran (10 kDa) was performed in primary WT and RNase L KO MEFs starved in medium containing 1% serum. (D)
The amount of fluorescent dextran internalized was quantified by marking the cell boundary, and the mean fluorescence inside the cell was normalized to the cell
surface area using ImageJ and graphed. Representative images from triplicate experiments are shown. Quantitation data in panels A and B are from the results
of three independent experiments and represent means standard errors (SE). P values from comparisons performed using Student’s t test are as shown.
Malathi et al.
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L (see Fig. S1 in the supplemental material) were pretreated with
Cytochalasin D (Cyto D), which inhibits actin polymerization, or
with Latrunculin A (Lat A), which prevents F-actin assembly and
inhibits polymerization, or were left untreated. Cells were then
transfected with 2-5A or with poly(I·C) to activate OAS and pro-
duce endogenous 2-5A, and RNase L activity was measured by
monitoring rRNA cleavage. RNase L activity in response to
poly(I·C) and, to a lesser extent, 2-5A was observed that was inde-
pendent of cytoskeletal disruption (Fig. 3C). Together, these data
indicate that the presence of the actin-binding protein Filamin A,
or perturbation of the actin network, does not affect RNase L
activity. Moreover, RNase L interacts with Filamin A only in the
absence of its activator, suggesting that RNase L-dependent mod-
ulation of the actin cytoskeleton does not require its enzymatic
activity.
RNase L and Filamin A reduce virus entry into cells. Many
viruses such as dengue virus and influenza virus use macropinocy-
tosis as a mechanism of viral entry into cells (40–42). We demon-
strated that cells lacking RNase L show an increase in nonselective
uptake of fluid-phase dextran by macropinocytosis (Fig. 2C), sug-
gesting that RNase L may play a role in forming a barrier for viral
entry into cells. Indeed, Filamin A functions as a scaffold for cy-
toskeletal rearrangement that is associated with virus infection
(12, 13) and RNase L may contribute to this activity via its inter-
action with Filamin A. We therefore tested the hypothesis that
RNase L and Filamin A function together to reduce virus entry.
Sendai virus (SeV) is a paramyxovirus that is known to induce
rearrangement of the actin cytoskeleton upon infection (2, 46); we
therefore compared the levels of entry of Sendai virus (SeV) into
M2 and A7 cells that lack or express both RNase L and Filamin A.
A7 cells are M2 cells reconstituted with Filamin A and are widely
used as control cells for the study of Filamin A (43, 47, 48). We
determined that A7 cells also express functional RNase L protein
(see Fig. S1 in the supplemental material). Entry of SeV into cells
was detected by immunofluorescence using antibodies against
SeV that recognize all structural proteins (49) (Fig. 4A) and quan-
tified by measuring the fluorescence in a defined region normal-
ized to the cell surface area. This analysis was performed at 1 h
postinfection to provide an indication of the impact of Filamin A
and RNase L on virus entry prior to replication and activation of
RNase L and other innate immune responses. In A7 cells that
express Filamin A and RNase L, most of the virus was restricted to
the cell membrane. In contrast, M2 cells that lack these proteins
exhibited 2.5-fold-higher levels of intracellular SeV staining
(Fig. 4A and C), suggesting that RNase L and Filamin A function
to restrict virus entry. To determine if RNase L deficiency alone
also led to increased virus entry, SeV entry was analyzed in WT
and RNase L KO MEFs (Fig. 4B). Consistent with the enhanced
uptake of dextran in RNase L KO MEFs (Fig. 2C), the intracellular
SeV immunofluorescence level was increased 4-fold in RNase L
KO compared to WT MEFs (Fig. 4B and D). Further quantifica-
tion of SeV entry by quantitative real-time PCR revealed a 40%
decrease in intracellular viral RNA levels in WT compared to KO
MEFs (Fig. 4E). Together, these data suggest that RNase L, per-
haps via its interaction with Filamin A, functions to inhibit virus
entry as a novel mechanism of its antiviral activity. To dissect the
relative contributions of RNase L and Filamin A in the inhibition
of viral entry and assess the potential role of RNase L enzymatic
activity in this function, we used RNase L- and Filamin A-deficient
M2 cells that had been stably transfected with Filamin A, WT
RNase L, or catalytically inactive (R667A) RNase L alone and in
combination as shown in Fig. 3A. Cells were infected with SeV or
EMCV for 1 h to allow viral entry and then washed with acidic
glycine to inactivate extracellular viruses. Intracellular virus was
quantified by quantitative real-time PCR for SeV RNA or plaque
assay for EMCV (45). SeV entry into M2 cells expressing WT,
R667A, or Filamin A proteins was inhibited by more than 3.5-log
and EMCV entry was reduced by 2-log compared to the levels seen
with M2 cells which lack both proteins (Fig. 4F and G). Strikingly,
coexpression of Filamin A protein with either WT or R667A mu-
tant RNase L resulted in a significant further inhibition of entry by
both viruses (Fig. 4F and G). Similar effects of Filamin A and WT
or R667A RNase L on virus titer were observed when the acidic
glycine wash was omitted; however, intracellular EMCV titers
FIG 3 Effect of Filamin A and actin cytoskeleton on RNase L activity. M2 stable cell lines expressing Myc-Filamin A and/or Flag-RNase L WT or Flag-RNase L
R667A were analyzed for expression of RNase L and Filamin A on immunoblots (A) and transfected with 10 M 2-5A (B), and RNase L-mediated cleavage of
rRNA (arrows) was analyzed on RNA chips using an Agilent 2100 Bioanalyzer. (C) HT1080 cells were pretreated with Cytochalasin D (Cyto D; 5 M),
Latrunculin A (Lat A; 0.5 M), or vehicle (DMSO) for 1 h followed by transfection with 10 M 2-5A or 2 g/ml of poly(I·C). Characteristic RNase L-generated
rRNA cleavage products (arrows) were detected as described for panel B. Representative images from three independent experiments are shown.
Antiviral Roles of RNase L-Filamin A Interaction
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were marginally higher, likely due to the prolonged exposure to
viable virus (see Fig. S3 in the supplemental material). These find-
ings demonstrate novel roles for RNase L and Filamin A in re-
stricting virus entry. While expression of either protein resulted in
a significant reduction in the level of virus entry, the presence of
both proteins further decreased virus entry levels, suggesting that
RNase L and Filamin A function as part of a mechanical barrier to
virus entry. More remarkable is the observation that the inhibition
of virus entry by RNase L occurs in a manner independent of its
enzymatic activity, suggesting a novel structural mechanism by
which RNase L mediates its antiviral activity. To evaluate the con-
tribution of RNase L-Filamin A interaction to viral entry, M2 cells
stably expressing Filamin A were transfected with vector alone,
full-length RNase L (WT), or N- and C-terminal deletion mutants
(N and C) that abolish and reduce Filamin A interactions,
respectively (Fig. 1C). Cells were then infected with SeV to allow
virus entry for 1 h, and intracellular virus was quantified as de-
scribed above. Expression of WT RNase L resulted in a significant
FIG 4 Regulation of virus entry by RNase L and Filamin A. (A and C) Immunofluorescence of A7 and M2 melanoma cells infected with SeV (40 HAU/ml) for
1 h. Unbound virus was removed, and cells were stained with antibody against SeV and detected using Alexa 633-conjugated secondary antibodies and imaged.
Virus entry was quantitated by measuring the mean fluorescence intensity (in thousands) in cells normalized to the cell surface area (n  10 from three
independent experiments). (B and D) WT and RNase L KO MEFs were infected, stained, and quantitated as described for panel A (n 10 from three independent
experiments). (E) WT and RNase L KO MEFs were infected with SeV (40 HAU/ml) for 1 h. After unbound virus was removed, entry was quantitated by
determining copy numbers of SeV genomic RNA strands by real-time quantitative PCR (qPCR) as described in Materials and Methods. (F and G) M2 stable cells
expressing Myc-Filamin A and/or Flag-RNase L WT or Flag-RNase L R667A were infected with SeV (40 HAU/ml) (F) or EMCV (MOI 1.0) (G) for 1 h and
washed briefly with acidic glycine to remove unbound extracellular viruses. Intracellular EMCV titers were determined by a plaque assay using L929 cells, and
copy numbers of SeV genomic RNA strands were determined by real-time qPCR and normalized to GAPDH mRNA levels. Student’s t test was used to determine
P values (as shown) for comparisons of M2 cells expressing Filamin A to cells expressing Filamin A and either RNase L WT or R667A. Data are representative of
the results of two independent experiments performed in triplicate standard deviations (SD).
Malathi et al.
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52-fold reduction in virus entry compared to the level seen with
cells lacking RNase L expression (Fig. 5, WT versus none). In
contrast, expression of theN RNase L mutant that does not bind
Filamin A led to a dramatic 23-fold increase in virus entry com-
pared to the level seen with WT RNase L (Fig. 5). TheC RNase L
mutant, which exhibits only slightly reduced Filamin A binding
compared to WT RNase L, resulted in a correspondingly modest
7-fold increase in SeV entry over that observed for WT RNase L
(Fig. 5). These results link RNase L-Filamin A interaction with the
restriction of viral entry and support an important role for this
interaction in barrier function.
Filamin A inhibits virus production. The absence of Filamin
A led to enhanced viral entry, suggesting that it may also impact
downstream virus production and release. To test this prediction,
we first measured viral genomic RNA following infection of M2
and A7 cells with SeV for 8 and 24 h. M2 cells that lack both RNase
L and Filamin A showed a greater than 6-fold increase in viral
RNA levels compared to A7 cells which express both proteins
(Fig. 6A). This observation correlated with a dramatically in-
creased accumulation of SeV proteins in M2 compared to A7 cells
at the 24-h time point (Fig. 6B). RNase L has been shown to exert
antiviral effects that result in a decrease in SeV titers in vitro and in
vivo (29, 45); therefore, the compromised antiviral effect observed
in M2 cells could have been due to the lack of detectable RNase L
in these cells. To specifically examine the antiviral effect of Filamin
A, we knocked down Filamin A in HT1080 cells that express func-
tional RNase L (Fig. 6F). SeV infection of Filamin A knockdown
and control cells resulted in a significant 3-fold increase in the
level of SeV genomic RNA in the supernatant of Filamin A knock-
down compared to control cell results at both 8 and 24 h postin-
fection (Fig. 6C). To assess the effect of Filamin A on virus pro-
duction and release, intracellular and extracellular SeV genomic
RNA was quantified following infection of HT1080 stable cells
with Filamin A knockdown and control cells (Fig. 6G) for 8 and
24 h. Filamin A knockdown resulted in an increase in the levels of
both intracellular and released SeV at all the time points, suggest-
ing that Filamin A impaired virus entry and led to a functional
decrease in virus production (Fig. 6D and E).
Filamin A potentiates the antiviral effect of RNase L. Coex-
pression of RNase L and Filamin A potently inhibited virus entry
at 1 h postinfection (Fig. 4F and G, Fig. 5). To evaluate the func-
tional impact of RNase L and Filamin A expression on virus pro-
duction, viral RNA or viral titers were measured at later time
points following SeV or EMCV infection of M2 cells that stably
express Filamin A and either WT or catalytically inactive (R667A)
RNase L (Fig. 3A). WT RNase L dramatically reduced SeV and
EMCV titers in the supernatant under all conditions tested. Ex-
pression of catalytically inactive RNase L or Filamin A alone re-
sulted in a more modest diminution of viral titers (Fig. 7) and
likely reflects the contribution of antiviral activity mediated by the
enzymatic activity of WT RNase L which occurs post-virus entry.
Coexpression of RNase L and Filamin A significantly reduced the
levels of viral RNA or titer (7- to 10-fold for SeV RNA and 1- to
2.5-log for EMCV PFU) compared to the results seen with either
protein alone (Fig. 7). However, the impact of expression of both
proteins on virus production was less dramatic than its effect on
virus entry (Fig. 4F and G), suggesting that Filamin A plays a more
prominent role in restricting virus entry (see, e.g., Fig. 3A). Our
findings support a model in which RNase L and Filamin A func-
tion together to provide a barrier to viral entry that does not re-
quire RNase L enzymatic activity (Fig. 8). Following viral infec-
tion, production of type I IFNs and 2-5A activates RNase L, which
dissociates from Filamin A and mediates antiviral activity via its
established enzymatic mechanisms (18).
DISCUSSION
Viral and bacterial pathogens interact with host plasma mem-
brane proteins that act as receptors as a first step in infection.
These receptors are linked to intercellular junctional proteins and
the intracellular cytoskeletal network, which together comprise a
physical barrier to pathogen entry (1). Disruption of this barrier is
essential for a productive infection; however, the mechanisms by
which the physical signals of infection are sensed by the host, and
how these signals activate established innate immune mediators to
initiate a host response, are not well understood. In this report, we
provide the first evidence that RNase L, an established mediator of
the innate immune response to viral and bacterial pathogens (18–
20, 29, 50), interacts with the actin-binding protein Filamin A to
modulate the actin cytoskeleton and inhibit virus entry into cells.
Upon infection and activation of its enzymatic activity, RNase L
dissociates from Filamin A to mediate its canonical antiviral sig-
naling and effector functions. Our report thus identifies a novel
FIG 5 Effect of RNase L and Filamin A interaction on viral entry. (A) M2 cells stably expressing Myc-Filamin A transfected with Flag-RNase L (full length),
Flag-RNase L (C), or Flag-RNase L (N) or with vector (none) were infected with SeV (40 HAU/ml) for 1 h and washed briefly with acidic glycine to remove
unbound extracellular viruses. Copy numbers of SeV genomic RNA strands were determined by real-time qPCR and normalized to GAPDH mRNA levels.
Student’s t test was used to determine P values (as shown). (B) Fold change in viral entry was normalized to WT data. *, P 0.01; **, P 0.001 (for comparisons
using Student’s t test).
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mechanism by which RNase L exerts its antiviral activity via an
interface with the actin cytoskeleton that is modulated in response
to the physical perturbation of this network.
The interaction between RNase L and Filamin A was detected
and mapped by coimmunoprecipitation to investigate their asso-
ciation in a cellular context. This analysis indicated that the
N-terminal portion of RNase L was required for coimmunopre-
cipitation with Filamin A (Fig. 1C; see also Fig. S2 in the supple-
mental material). A small reduction in the IP of Filamin A with the
N RNase L mutant (Fig. 1C) but not in the reciprocal IP (see
Fig. S2) was observed, suggesting that C-terminal residues may
also influence the interaction. Additional work is required to iden-
tify the specific RNase L residues that mediate its association with
a Filamin A complex. This information will permit the generation
of interaction-deficient mutants to assess the role of this interac-
tion in antiviral activities. Interestingly, despite the presence of the
8.5 ankyrin repeat domains in this region that are known to me-
diate protein-protein interactions, this is the first report of a pro-
tein that interacts with RNase L via its N terminus. The ankyrin
repeat domains that comprise the RNase L N terminus contain
sites that are critical to coordination of the binding of its activator,
2-5A (27, 28, 51). 2-5A is produced in cells following virus infec-
tion or IFN treatment, and its binding to RNase L induces confor-
mational change and dimerization that convert RNase L into an
active endoribonuclease (21, 51, 52). As predicted from the over-
lap between the 2-5A binding sites and the Filamin A interaction
region, the RNase L-Filamin A interaction was disrupted follow-
ing virus infection or direct treatment of cells with 2-5A (Fig. 1E
and F). Thus, it is likely that Filamin A interacts with inactive
monomeric RNase L. Conversely, the presence of Filamin A did
not impair RNase L activation (Fig. 3B). These results may reflect
a stronger affinity of RNase L for 2-5A compared to that seen with
Filamin A and may involve distinct residues that mediate these
interactions. Another potential impact of the association of RNase
L with Filamin A via its N terminus is that the pseudokinase do-
main, which is critical for RNase L homodimerization and inter-
action with all heterologous RNase L binding partners reported to
date, remains free (27, 28, 53). This orientation may function to
anchor RNase L to the cytoskeletal complex while allowing the
pseudokinase domain to interact with regulatory molecules. For
example, the pseudokinase domain also contains a site that is re-
quired for 2-5A binding (27); thus, access to the pseudokinase
domain may provide an initial docking site for 2-5A, thereby pro-
moting subsequent dissociation from Filamin A and dimeriza-
tion. Together, our data suggest that Filamin A, by virtue of its
actin-binding ability, may sequester a pool of RNase L in the cy-
toskeleton that dissociates from this complex upon activation. In a
related study, RNase L was isolated in association with cytoskeletal
FIG 6 Filamin A inhibits SeV production and release. (A) A7 or M2 cells were infected with SeV (40 HAU/ml), and viral yield levels at the indicated times were
quantitated by determining SeV RNA copy numbers in culture supernatants by qPCR. Copy numbers were interpolated from a T7-transcribed RNA standard
and are expressed as copy number per ml of supernatant. (B) Cell lysates of A7 and M2 cells infected with SeV as described for panel A were analyzed for viral
protein expression at the indicated times using anti-SeV antibodies. -Actin was used as a loading control. (C) HT1080 cells transfected with control small
interfering RNA (Ctrl siRNA) or Filamin A siRNA were infected with SeV, and viral yield levels were determined as described for panel A. Student’s t test was used
for comparisons. *, P 0.001 (for comparisons to control shRNA cell results performed using Student’s t test). HT1080 shRNA Filamin A knockdown or control
stable cell lines were infected with SeV (40 HAU/ml) for 1 h. Unbound virus was washed with PBS and replaced with complete growth medium. (D and E) Cell
samples and supernatant were collected at the indicated times, and the intracellular (D) or extracellular (supernatant) (E) SeV genomic RNA copy number was
determined as described for panel A. The intracellular viral copy number was normalized to GAPDH mRNA levels. (F and G) Knockdown of Filamin A using
control (Ctrl) and Filamin A (FilA) siRNAs (F) or an shRNA-expressing stable cell line (G) is shown on immunoblots. Data are representative of the results of
two independent experiments performed in triplicate SD. *, P 0.01; **, P 0.001 (for comparisons to control shRNA cell results performed using Student’s
t test).
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proteins in a detergent-insoluble cell fraction and was released to
the cytosol upon stimulation with the phorbol ester mitogen 12-
O-tetradecanoylphorbol-13-acetate (TPA). TPA treatment in-
duced phosphorylation of RNase L, which led to its activation and
dissociation from cytoskeletal components (54). Furthermore,
proteomic analysis of RNase L-interacting proteins identified ex-
tracellular matrix (ECM) and cytoskeletal proteins as binding
partners (31). These findings suggest that the association of RNase
L with the cytoskeleton is both dynamic and context specific.
The intricate network of actin filaments associated with the
plasma membrane presents a physical barrier that viruses must
disrupt to gain entry into the cytoplasm. The interaction of RNase
L with Filamin A suggested that RNase L may impact cellular
processes regulated by actin dynamics. In support of this predic-
tion, we observed distinct morphologies in MEFs lacking RNase L
that correlated with reduced levels of filamentous actin and in-
creased dextran uptake by macropinocytosis (Fig. 2). In contrast,
RNase L KO bone marrow-derived macrophages (BMMs) were
previously reported to exhibit reduced uptake of FITC-dextran
compared to WT BMMs, whereas phagocytic activity was not af-
fected (55). The different results reported in these studies may
reflect fundamental differences in pinocytic activity and innate
immune responses between MEFs and BMMs. In line with the
observed increase in macropinocytosis, RNase L KO MEFs
showed increased entry of SeV and EMCV, suggesting that RNase
L serves as a barrier for virus entry. In a similar role, RNase L
inhibited translocation of enteropathic E. coli across intestinal ep-
ithelial cells by regulating tight-junction proteins and barrier in-
tegrity (32). Together, these findings suggest a novel barrier func-
tion for RNase L in pathogen exclusion.
Our finding that RNase L inhibits virus entry and interacts with
Filamin A suggested that Filamin A may also function in inhibit-
ing viral entry into cells. Consistent with this prediction, infection
of Filamin A-deficient and -competent M2 melanoma cells with
either SeV or EMCV demonstrated increased virus entry in the
absence of Filamin A (Fig. 4A, F, and G). Furthermore, M2 cells
lacking either RNase L or Filamin A displayed significantly more
virus entry and cells lacking both proteins showed a further in-
crease in virus entry (Fig. 4A, F, and G). This finding indicated
roles for both RNase L and Filamin A in limiting virus entry. In
support of a critical role for the interaction of RNase L and Filamin
A in restricting virus entry, RNase L deletion mutants that abol-
FIG 7 Filamin A potentiates RNase L antiviral effect. M2 cells expressing Myc-Filamin A and/or Flag-RNase L WT or Flag-RNase L R667A were infected with
SeV (40 HAU/ml) (A and B) or EMCV (MOI  1.0) (C and D) for the indicated times. (A and B) Viral yields at 8 h (A) and 24 h (B) were quantitated by
determining SeV RNA copy numbers in culture supernatants by qPCR. Copy numbers were interpolated from the T7-transcribed RNA standard and are
expressed as copy number per ml of supernatant. (C and D) EMCV viral titers were determined by a plaque assay using L929 cells after 4 h (C) or 8 h (D). P values
are as shown for comparisons performed using Student’s t test. Data are representative of the results of two independent experiments performed in triplicate
SD.
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ished or reduced Filamin A interaction resulted in a proportional
decrease in barrier function and increase in virus entry (Fig. 5).
Interestingly, the presence of either the N- or C-terminal regions
of RNase L reduced viral entry compared to that observed in
RNase L-deficient cells, suggesting that this activity is mediated by
multiple regions and interacting proteins. Thus, Filamin A may
serve as the primary cytoskeletal contact for the RNase L N termi-
nus, with other cytoskeletal proteins interacting with the internal
and C-terminal regions. Consistent with this interpretation, cyto-
skeletal proteins were recently identified as a major class of candi-
date RNase L interactors (31) and we validated RNase L interac-
tion with a cytoskeletal protein through its C terminus (B. A.
Hassel and H. J. Ezelle, unpublished data). The extent to which
RNase L interaction with Filamin A and other cytoskeletal pro-
teins enhances barrier function requires additional studies to map
and mutate the interaction sites and to generate interaction-
deficient mutants. Our work further demonstrated that both WT
and catalytically inactive RNase L were competent to reduce virus
entry when transfected into RNase L-deficient cells. To our
knowledge, this observation of the novel role of RNase L in limit-
ing virus entry represents the first report of its antiviral function
that is independent of enzymatic activity. Analysis of intracellular
and extracellular viral genomic RNA at later times postinfection
demonstrated a significant, but more modest, combined effect of
RNase L and Filamin A on viral replication and release from cells
compared to entry (Fig. 6D and E and 7). This activity exhibited
greater dependence on RNase L enzymatic function, which is an
important component of antiviral mechanisms post-entry and
replication. Taken together, our results support a model in which
RNase L and Filamin A form a structural complex to restrict viral
entry in naive cells (Fig. 8). Invading viruses alter the actin cyto-
skeleton, in part by targeting actin-binding proteins to facilitate
their entry. These alterations, in turn, disrupt the RNase
L-Filamin A interaction to release RNase L from the barrier com-
plex and promote downstream antiviral signaling.
Innate immune sensors and effectors that have historically
been thought to function only in the context of pathogen infection
have recently been reported to play key roles in host homeostatic
activities in the absence of pathogen threat. Specifically, several
IFN-stimulated genes (ISG) have been shown to modulate the
actin cytoskeleton and enhance barrier function as a baseline de-
fense against pathogen infection. For example, the PKR antiviral
protein kinase binds to and inhibits an actin-severing protein,
gelsolin, to alter actin dynamics limiting viral entry and to main-
tain a basal innate immune defense (8). IFITM is an ISG that is
part of the tight-junction complex and promotes barrier function
from HCV entry in response to IFN (56). RIG-I is a PRR that
senses viral RNAs, including the products of RNase L cleavage
(29), to activate signaling pathways that induce type I IFNs (57,
58) and is associated with the actin cytoskeleton (59, 60). The
localization of RIG-I, and other innate immune signaling pro-
teins, including RNase L and PKR, close to the plasma membrane-
proximal cytoskeleton is thought to facilitate the formation of
viral RNA granules that act as platforms for virus sensing and
signaling upon viral entry (61). Furthermore, the close association
of viral RNA with RNase L and RIG-I provides a mechanism by
which the viral RNA products of RNase L cleavage can activate
RIG-I. In addition, the ISG15 ubiquitin-like protein that mediates
diverse IFN-induced antiviral functions also modulates the actin
cytoskeleton and cell architecture and promotes cell migration by
FIG8 Proposed antiviral mechanism of RNase L-Filamin A interaction. RNase L-Filamin A interaction prevents viral entry and promotes resistance under basal
conditions by maintaining a barrier. Virus infection alters actin dynamics and disrupts RNase L-Filamin A interaction to release RNase L from the scaffold.
dsRNAs produced during viral infections activate OAS to produce 2-5A, which in turn binds monomeric, inactive RNase L and converts it to an active dimer with
potent endoribonuclease activity that mediates an antiviral response. CM, cell membrane; PRR, pattern recognition receptor.
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stabilizing proteins that promote migration and invasion (62).
The dual roles these ISGs serve in the absence and presence of
pathogens provide an efficient strategy to protect against future
infection and to rapidly respond upon pathogen exposure. Our
report thus identifies RNase L as the latest entry in a growing list of
innate immune effectors that mediate critical host defense activi-
ties under basal conditions and following pathogen infection. Vir-
tually all viruses remodel the actin network to optimize multiple
aspects of their infection cycle; therefore, an understanding of the
host proteins and mechanisms underlying these regulatory nodes
may provide opportunities for the development of broad-
spectrum antiviral agents that target these activities.
MATERIALS AND METHODS
Cells, reagents, and plasmids. HEK293T (provided by Fan Dong, Uni-
versity of Toledo), HT1080, and L929 cells were cultured in Dulbecco’s
modified minimal essential medium (DMEM) with 10% fetal bovine se-
rum (Invitrogen, Carlsbad, CA) and 100 g/ml penicillin/streptomycin.
WT and RNaseL/ (RNase L KO) MEFs, primary and transformed with
simian virus 40 (SV40) large T antigen (a gift from Robert Silverman,
Cleveland Clinic), were grown in RPMI 1640 supplemented with strepto-
mycin (100 g/ml), penicillin (100 units/ml), 2 mmol/liter glutamine,
and 10% fetal bovine serum (Invitrogen, Carlsbad, CA). HeLa M cells
expressing pcDNA3 vector, WT RNase L, RNase L R667A (nuclease
dead), or RNase L R462Q (dimerization defective and with 3-fold-
reduced enzyme activity) kindly provided by Robert Silverman, Cleveland
Clinic, were maintained in DMEM with 10% fetal bovine serum (Invitro-
gen, Carlsbad, CA) and 100g/ml penicillin-streptomycin supplemented
with 250 g/ml G418 (Life Technologies, Carlsbad, CA). M2 melanoma
cells lacking Filamin A and A7 cells derived from M2 cells by stably ex-
pressing Filamin A (provided by J. H. Hartwig, Harvard Medical School,
Boston, MA) were cultured in Dulbecco’s modified minimal essential
medium with 10% fetal bovine serum (Invitrogen, Carlsbad, CA) and
100g/ml penicillin-streptomycin. A7 cells were maintained in complete
DMEM with 0.5 mg/ml G418 (Life Technologies, Carlsbad, CA). All
chemicals, unless indicated otherwise, were from Sigma-Aldrich (St.
Louis, MO). Antibody to Flag tag (monoclonal and polyclonal), Flag-M2
agarose beads, Myc-EZview beads, and -actin were from Sigma (St.
Louis, MO), Myc tag (monoclonal and polyclonal) was from Cell Signal-
ing, Inc. (Danvers, MA), Filamin A (monoclonal) was from Neomarkers
(Fremont, CA), and polyclonal antibody was from Santa Cruz Biotech-
nology (Santa Cruz, CA). Goat anti-Sendai virus antibody raised against
the Cantell strain which recognizes all structural antigens was used for
immunofluorescence (Meridian Life Sciences). Rabbit anti-SeV antibody
from MBL (Woburn, MA) was used for immunoblots. RNase L monoclo-
nal antibody was kindly provided by Robert Silverman (Cleveland Clinic).
Anti-mouse IgG and anti-rabbit IgG horseradish peroxidase (HRP)-
linked secondary antibodies were from Cell Signaling, Inc. (Danvers,
MA), and ECL reagents were from GE Healthcare (Piscataway, NJ). FITC-
labeled dextran (10 kDa), Alexa 488-labeled phalloidin, and Alexa Fluor
633 donkey anti-goat IgG were from Life Technologies. Cytochalasin D
and Latrunculin A were obtained from Cayman Chemicals (Ann Arbor,
MI) and used at 5 M and 0.5 M dissolved in dimethyl sulfoxide
(DMSO). Sendai virus (Cantell strain; Charles River Laboratories),
EMCV, and preparation and transfection of 2-5A have been described
previously (45). Plasmids Flag-RNase L, Flag-RNase L R667A, Flag-RNase
L (residues 1 to 335;C), Flag-RNase L (residues 386 to 741;N) (kindly
provided by Robert Silverman, Cleveland Clinic), and Myc-Filamin A
(Addgene) were transfected using Lipofectamine 2000 per the manufac-
turer’s instructions.
Stable cell lines. Filamin A silencing and nonsilencing small harpin
RNAs (shRNAs) were generated as suggested by the manufacturer using a
GIPZ-lentiviral shRNA system, and knockdown HT1080 cells or controls
were selected with 1g/ml of puromycin (Open Biosystems/Thermo Sci-
entific, Pittsburgh, PA). M2 cells transfected with Myc-Filamin A were
selected in the presence of 0.5 mg/ml of G418 to generate stable M2 Fil-
amin A (FLNA) cells. M2 cells or M2 FLNA cells were transfected with
Flag-CMV2 vector, Flag-RNase L, or Flag-RNase LR667A along with
pbabe-puro plamid and selected in the presence of 1g/ml of puromycin
to generate stable cell lines. Cells with comparable levels of expression of
Filamin A and/or RNase L were selected and used.
Dextran uptake assays. WT and RNase L KO MEFs were grown on
glass coverslips and replaced with RPMI medium containing 1% serum
for 18 h. Cells were incubated with 25g/ml of FITC-dextran (10 kDa) for
1 h at 37°C, washed twice in phosphate-buffered saline (PBS), fixed, and
mounted in Vectashield with DAPI (4=,6-diamidino-2-phenylindole)
(Vector Laboratories, Burlingame, CA). Cells were imaged by the use of a
Leica TCS SP5 multiphoton laser scanning confocal microscope, and flu-
orescence was quantitated using NIH ImageJ software. A minimum of 10
fields from triplicate experiments were analyzed.
Virus infection andvirus assays.Cells (2 105 in 12-well plates) were
grown overnight, washed two times with PBS, and infected with EMCV
(strain K) at a multiplicity of infection (MOI) of 1.0 or with Sendai virus
(SeV) at 40 hemagglutination units (HAU)/ml in media without serum.
After 1 h, media were removed, cells were washed with PBS, and complete
media were added until they were harvested. EMCV titers in supernatants
were determined by a plaque assay after 4 h and 8 h in serial dilutions using
L929 cells. SeV was quantified after 8 h and 24 h from supernatants by
RNA isolation and real-time PCR, and copy numbers were interpolated
from a T7-transcribed RNA standard and expressed as copy numbers per
ml of supernatant as previously described (45). To determine the effect on
SeV production and release, control or Filamin A shRNA-expressing sta-
ble HT1080 cells were infected with SeV (40 HAU/ml) for 8 h or 24 h.
Intracellular SeV RNA copy numbers were determined by reverse
transcription-PCR (RT-PCR) and normalized to GAPDH
(glyceraldehyde-3-phosphate dehydrogenase), and extracellular RNA
levels were determined for the same samples from culture supernatants.
For assays of viral entry, 1 106 cells were infected with EMCV (MOI
1.0) or SeV (40 HAU/ml) at 37° C for 1 h. The inoculum of virus was
removed, and the cells were treated with acid glycine (pH 3.0) for 2 min to
inactivate unbound extracellular virus (5, 63–67). M2 cells stably express-
ing Filamin A were transiently transfected with Flag-RNase L (full length),
Flag-RNase L, Flag-RNase L (residues 1 to 335; C), Flag-RNase L (resi-
dues 386 to 741;N), or Flag vector alone (1 105 cells in 12-well dishes)
and infected with SeV (40 HAU/ml) as described above to monitor virus
entry. Following virus attachment, virus internalization was allowed to
proceed for 1 h. Cell samples were collected, and the intracellular titer of
virus in each sample was determined by a plaque assay for EMCV after
repeat freeze-thaw cycles or by determining SeV RNA copy numbers nor-
malized to GAPDH by RT-PCR. Experiments were performed two times,
and data are shown as standard deviations (SD) for experiments per-
formed in triplicate.
Monitoring RNase L activity in intact cells. Cells were transfected
with 10 M 2-5A or 2 g/ml of synthetic dsRNA [poly(I·C)], using Lipo-
fectamine 2000. In some experiments, cells were pretreated with Cytocha-
lasin D (5 M) or Latrunculin A (0.5 M) or vehicle (DMSO) for 1 h
followed by 2-5A transfection. At the indicated times, the total RNA was
isolated from transfected cells using Trizol reagent (Invitrogen/Life Tech-
nologies) and quantitated by measuring absorbance at 260 nm using a
NanoDrop spectrophotometer (Thermo Scientific, Wilmington, DE).
RNAs (2 g) were separated on RNA chips and analyzed with a 2100
Bioanalyzer (Agilent Technologies) to monitor characteristic rRNA cleav-
age products generated by RNase L activity as described previously (44).
Coimmunoprecipitation and immunoblotting. HEK293T cells ex-
pressing Myc-Filamin A along with various Flag-RNase L constructs (WT,
R667A, residues 1 to 335 [C] or residues 386 to 741[N]) were left
untreated or transfected with 10 M 2-5A or infected with EMCV (MOI
 1.0) for 1 h and harvested. Cells expressing Myc or Flag tag alone were
used as controls. Cells were washed with ice-cold PBS and lysed in buffer
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containing 0.5% NP-40, 90 mM KCl, 5 mM magnesium acetate, 20 mM
Tris (pH 7.5), 5 mM  mercaptoethanol, 0.1 M phenylmethylsulfonyl
fluoride (PMSF), 0.2 mM sodium orthovanadate, 50 mM NaF, 10 mM
glycerophosphate, and protease inhibitor (Roche Diagnostics, Indianap-
olis, IN) on ice for 20 min. The lysates were clarified by centrifugation at
10,000 g (at 4°C for 20 min). Clarified cell lysates were precleared and
mixed with control IgG, FlagM2-agarose, or Myc-EZview beads and ro-
tated end to end of 1 h or overnight at 4°C. The beads were collected and
washed five times in lysis buffer. Cell lysates (2 mg) of HeLa M cells
expressing RNase L (WT) or the RNase L R667A mutant or the RNase L
R462Q mutant were subjected to immunoprecipitation using Filamin A
polyclonal antibodies (Bethyl Laboratories, Montgomery, TX) and con-
trol IgG antibodies. The immunoprecipitated proteins were dissociated
by boiling in Laemmli sample buffer, separated on 8% or 10% SDS-
polyacrylamide gels, transferred to nitrocellulose membrane (Bio-Rad,
Hercules, CA), and subjected to immunoblotting. Membranes were
probed with different primary antibodies according to the manufacturer’s
protocols. Membranes were washed with Tris-buffered saline (TBS) with
1% Tween 20 and incubated with goat anti-mouse or goat anti-rabbit
antibody tagged with horseradish peroxidase (Cell Signaling, Danvers,
MA) for 1 h. Proteins in the blots were detected by enhanced chemilumi-
nescence (GE Healthcare).
Immunofluorescence assay (IFA). Cells were seeded on glass cover-
slips 24 h prior to use for IFA. Infected or uninfected cells were rinsed in
cold PBS and fixed with 4% paraformaldehyde (EM Sciences, Hatfield,
PA) for 15 min and permeabilized with 0.2% Triton X-100 for 5 min. After
washing and blocking in 1% bovine serum albumin (BSA) PBS, the cells
were reacted with primary antibodies (1:300, overnight at 4°C) reactive
against all structural SeV antigens followed by washing and incubation
with fluorescent dye-conjugated secondary antibodies and Alexa 633 don-
key anti-goat IgG (Molecular Probes) (1:100; 1 h at 4°C). F-actin was
visualized by staining with Alexa 488 phalloidin for 1 h at 37°C according
to the manufacturer’s instructions (Molecular Probes). Cells were
mounted in Vectashield with DAPI to stain the nucleus (Vector Labora-
tories, Burlingame, CA). Fluorescence and confocal microscopy assess-
ments were performed with a Leica CS SP5 multiphoton laser scanning
confocal microscope (Leica Microsystems, Weitzler, Germany) and quan-
titated using ImageJ software (National Institutes of Health). Images were
processed using Adobe Photoshop CS4 (Adobe, San Jose, CA). More than
10 cells (from two coverslips) were analyzed for each condition.
Statistical analysis. Student’s t tests were used for determining the
statistical significance of the results of comparisons between groups. P val-
ues were obtained from a two-tailed, unpaired Student’s t test and are
shown for all analyses. P 0.05 was considered significant in all cases.
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